Damora Therapeutics (DMRA) Long-Term Deferred Tax (2023 - 2024)
Damora Therapeutics (DMRA) posted Long-Term Deferred Tax of $67.2 million for Q4 2024, up 6.02% on a QoQ basis from $63.4 million in Q4 2023, and up 6.02% year-over-year from $63.4 million in Q1 2024.
Damora Therapeutics (DMRA) Long-Term Deferred Tax (2023 - 2024) Analysis & Trends
Damora Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $67.2 million for Q4 2024.
- Quarterly Long-Term Deferred Tax rose 6.02% year-over-year to $67.2 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $67.2 million (up 6.02% YoY) and the FY2024 annual result came in at $67.2 million, up 6.02% from the prior year.
- Long-Term Deferred Tax was $67.2 million for Q4 2024 at Damora Therapeutics, up from $63.4 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $67.2 million in Q4 2024 and bottomed at $63.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 67.23 Mn |
| Dec 31, 2023 | 63.41 Mn |